Brian G. Feagan
Impact in
- Genetics top 0.01%
- Inflammatory Bowel Disease
- Epidemiology top 0.01%
- Microscopic Colitis
- Autoimmune and Inflammatory Disorders
Papers in
- Genetics 578
- Inflammatory Bowel Disease 578
- Epidemiology 216
- Microscopic Colitis 193
- Autoimmune and Inflammatory Disorders 29
- Co-authors
- William J. Sandborn (251 shared papers)Paul J. Rutgeerts (64 shared papers)Jean Fred Colombel (81 shared papers)Bruce E. Sands (100 shared papers)Stephen B. Hanauer (23 shared papers)Gary R. Lichtenstein (17 shared papers)Stefan Schreiber (49 shared papers)Stephen B. Hanauer (49 shared papers)
- Journals
- Gastroenterology (143 papers)Inflammatory Bowel Diseases (80 papers)The American Journal of Gastroenterology (69 papers)Journal of Crohn s and Colitis (64 papers)Alimentary Pharmacology & Therapeutics (58 papers)
- Partner nations
- CanadaUnited StatesBelgium
In The Last Decade
Brian G. Feagan
688 papers receiving 71.0k citations
Brian G. Feagan's Hit Papers
Peers
Comparison fields: 5 of 163
- Genetics 52.0k
- Epidemiology 22.6k
- Gastroenterology 3.3k
- Immunology 12.4k
- Hematology 3.4k
Countries citing papers authored by Brian G. Feagan
This map shows the geographic impact of Brian G. Feagan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian G. Feagan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian G. Feagan more than expected).
Fields of papers citing papers by Brian G. Feagan
This network shows the impact of papers produced by Brian G. Feagan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian G. Feagan. The network helps show where Brian G. Feagan may publish in the future.
Co-authors
The 25 scholars most cited alongside Brian G. Feagan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 713 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Hit paper breakdown → | 2002 | 3498 |
| 2 | Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis Hit paper breakdown → | 2005 | 3239 |
| 3 | Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis Hit paper breakdown → | 2013 | 2390 |
| 4 | Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease Hit paper breakdown → | 2013 | 2300 |
| 5 | Infliximab Maintenance Therapy for Fistulizing Crohn's Disease Hit paper breakdown → | 2004 | 1801 |
| 6 | Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target Hit paper breakdown → | 2015 | 1517 |
| 7 | Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease Hit paper breakdown → | 2016 | 1476 |
| 8 | Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis Hit paper breakdown → | 2017 | 1423 |
| 9 | Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial Hit paper breakdown → | 2012 | 1314 |
| 10 | Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial Hit paper breakdown → | 2008 | 1038 |
| 11 | A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis Hit paper breakdown → | 2006 | 1008 |
| 12 | Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease Hit paper breakdown → | 2012 | 953 |
| 13 | Certolizumab Pegol for the Treatment of Crohn's Disease Hit paper breakdown → | 2007 | 940 |
| 14 | Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis Hit paper breakdown → | 2013 | 798 |
| 15 | Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease Hit paper breakdown → | 2004 | 780 |
| 16 | Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis Hit paper breakdown → | 2011 | 780 |
| 17 | Natalizumab Induction and Maintenance Therapy for Crohn's Disease Hit paper breakdown → | 2005 | 753 |
| 18 | Methotrexate for the Treatment of Crohn's Disease Hit paper breakdown → | 1995 | 730 |
| 19 | Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry Hit paper breakdown → | 2006 | 730 |
| 20 | The safety of vedolizumab for ulcerative colitis and Crohn's disease Hit paper breakdown → | 2016 | 664 |
About Brian G. Feagan
Brian G. Feagan is a scholar working on Genetics, Epidemiology, Immunology, Surgery and Gastroenterology, having authored 713 papers that have together received 73.3k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (578 papers), Microscopic Colitis (193 papers), Eosinophilic Esophagitis (51 papers), Helicobacter pylori-related gastroenterology studies (38 papers), Biosimilars and Bioanalytical Methods (32 papers), Autoimmune and Inflammatory Disorders (29 papers), Immunodeficiency and Autoimmune Disorders (24 papers) and Health Systems, Economic Evaluations, Quality of Life (20 papers). The work is most often cited by research in Genetics (52.0k citations), Epidemiology (22.6k citations), Gastroenterology (3.3k citations), Immunology (12.4k citations) and Hematology (3.4k citations). Brian G. Feagan has collaborated with scholars based in Canada, United States and Belgium. Frequent co-authors include William J. Sandborn, Paul J. Rutgeerts, Jean Fred Colombel, Bruce E. Sands, Stephen B. Hanauer, Gary R. Lichtenstein, Stefan Schreiber, Stephen B. Hanauer, Geert D’Haens and Daniel Rachmilewitz. Their work appears in journals such as Gastroenterology, Inflammatory Bowel Diseases, The American Journal of Gastroenterology, Journal of Crohn s and Colitis and Alimentary Pharmacology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.